



Fax completed form to: (855) 840-1678
 If this is an URGENT request, please call (800) 882-4462
 (800.88.CIGNA)

Erbitux (cetuximab)

PHYSICIAN INFORMATION			PATIENT INFORMATION		
* Physician Name:			*Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this form are completed.*		
Specialty:	* DEA, NPI or TIN:				
Office Contact Person:			* Patient Name:		
Office Phone:			* Cigna ID:	* Date of Birth:	
Office Fax:			* Patient Street Address:		
Office Street Address:			City:	State:	Zip:
City:	State:	Zip:	Patient Phone:		
Urgency: <input type="checkbox"/> Standard <input type="checkbox"/> Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)					
Medication Requested: <input type="checkbox"/> Erbitux Is this a new start? <input type="checkbox"/> Yes <input type="checkbox"/> No Start date: _____ Dose: _____ Frequency of therapy: _____ Length of therapy: _____ ICD10: _____					
What is your patient's current height? _____ What is your patient's current weight? _____ Will this medication be given concurrently with other agents? <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, please specify: _____					
Where will this medication be obtained? <input type="checkbox"/> Accredo Specialty Pharmacy** <input type="checkbox"/> Retail pharmacy <input type="checkbox"/> Prescriber's office stock (billing on a medical claim form) <input type="checkbox"/> Home Health / Home Infusion vendor <input type="checkbox"/> Other (please specify): _____ **Cigna's nationally preferred specialty pharmacy					
<i>**Medication orders can be placed with Accredo via E-prescribe - Accredo (1640 Century Center Pkwy, Memphis, TN 38134-8822 NCPDP 4436920), Fax 888.302.1028, or Verbal 866.759.1557</i>					
Facility and/or doctor dispensing and administering medication: Facility Name: _____ State: _____ Tax ID#: _____ Address (City, State, Zip Code): _____					
Is your patient a candidate for home infusion? Yes <input type="checkbox"/> No <input type="checkbox"/> Does the physician have an in-office infusion site? Yes <input type="checkbox"/> No <input type="checkbox"/>					
Is the requested medication for a chronic or long-term condition for which the prescription medication may be necessary for the life of the patient? <input type="checkbox"/> Yes <input type="checkbox"/> No					
What is your patient's diagnosis? <input type="checkbox"/> colorectal cancer (CRC) <input type="checkbox"/> head/neck cancer <input type="checkbox"/> non-small cell lung cancer (NSCLC) <input type="checkbox"/> penile cancer <input type="checkbox"/> skin cancer <input type="checkbox"/> other (please specify): _____					
Clinical Information (if CRC) Does your patient have advanced or metastatic disease? Yes <input type="checkbox"/> No <input type="checkbox"/> (if CRC) Does your patient have KRAS or NRAS wild-type disease? Yes <input type="checkbox"/> No <input type="checkbox"/> (if CRC) Does your patient's tumor express epidermal growth factor receptor (EGFR)? Yes <input type="checkbox"/> No <input type="checkbox"/> (if head/neck) Is Erbitux being given with radiation as primary treatment? Yes <input type="checkbox"/> No <input type="checkbox"/> (if yes) Is this new start of therapy or continuation of therapy? new start <input type="checkbox"/> continued therapy <input type="checkbox"/> (if continued therapy) How many weeks of treatment has your patient already received? _____ (if head/neck or skin) Does your patient have squamous cell carcinoma? Yes <input type="checkbox"/> No <input type="checkbox"/>					

(if skin) Does your patient have regional recurrence, distant metastases OR inoperable positive regional lymph nodes? Yes No

(if penile) Will Erbitux be used as single agent therapy? Yes No

(if NSCLC or penile) Does your patient have metastatic disease? Yes No

(if NSCLC or penile) Is Erbitux being given as second-line chemotherapy? Yes No

(if NSCLC) Will Erbitux be given in combination with Gilotrif (afatinib)? Yes No

(if NSCLC) Does your patient have EGFR-positive disease? Yes No

(if yes) Did your patient have disease progression on any of the following: Gilotrif, Iressa, Tarceva? Yes No

Additional pertinent information (including disease stage, prior therapy, performance status, and names/doses/admin schedule of any agents to be used concurrently).

Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan or insurer its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature: _____ **Date:** _____

Save Time! Submit Online at: www.covermymeds.com/main/prior-authorization-forms/cigna/ or via SureScripts in your EHR.

Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at cigna.com.

v061019

"Cigna" is a registered service mark, and the "Tree of Life" logo is a service mark, of Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Such operating subsidiaries include, for example, Cigna Health and Life Insurance Company and Cigna Health Management, Inc. Address: Cigna Pharmacy Services, PO Box 42005, Phoenix AZ 85080-2005